The ‘uncomfortable’ ASX stocks that this fundie has an eye on

CSL has disappointed the market on a number of fronts. The sudden change of CEO clearly surprised the market. The revenue performance of CSL’s Behring unit – which makes treatments from collected plasma – was weaker than expected, thanks to challenges with albumin, a hospital drug derived from plasma, in China, US-Medicare changes and greater competitive intensity.

Source: https://www.afr.com/markets/equity-markets/the-uncomfortable-asx-stocks-that-this-fundie-has-an-eye-on-20260330-p5zjuy